BMS to buy MyoKardia for access to late-stage heart disease drug

The $13 billion deal will bolster the big pharma firm's cardiovascular disease pipeline

Source: Chemical and Engineering News - October 9, 2020 Category: Chemistry Authors: Lisa M. Jarvis Source Type: research